Watch WVE. Know when insiders buy.
One email the day a filing lands. Free.
WVE
Wave Life Sciences, Inc.
3.78
−0.10 −2.58%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $744.8MP/E —DIV YIELD —FCF YIELD -25.93%REV TTM —NET INCOME −$202.5MNET CASH —52W 3.64 – 21.31SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.3M | −73.9% | — | −$73.8M | −$69.4M | — | -0.34 | −$53.6M | $884K | −$54.5M | Jul 30 |
| Q1 2026 · Mar 31 | $38.2M | +316.9% | — | −$31.3M | −$26.1M | — | -0.13 | −$59.6M | $438K | −$60M | Jul 30 |
| Q4 2025 · Dec 31derived | — | — | — | −$56.5M | −$53.2M | −281.8% | -0.29 | −$33.8M | −$1K | −$33.8M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$56.4M | −$53.9M | — | -0.32 | −$44.7M | $248K | −$44.9M | Nov 10 |
| Q2 2025 · Jun 30 | $8.7M | −55.8% | — | −$52.8M | −$50.5M | — | -0.31 | −$46M | $306K | −$46.3M | Jul 30 |
| Q1 2025 · Mar 31 | $9.2M | −26.8% | — | −$49.8M | −$46.9M | — | -0.29 | −$63M | $165K | −$63.2M | Jul 30 |
| Q4 2024 · Dec 31derived | — | — | — | $23M | $29.3M | — | 0.27 | −$43.6M | $86K | −$43.7M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$63.9M | −$61.8M | −951.9% | -0.47 | −$46.5M | $383K | −$46.9M | Nov 10 |
| Q2 2024 · Jun 30 | $19.7M | — | — | −$35M | −$32.9M | — | -0.25 | −$27.5M | $52K | −$27.5M | Nov 10 |
| Q1 2024 · Mar 31 | $12.5M | — | — | −$34.5M | −$31.6M | — | -0.24 | −$33.4M | $417K | −$33.8M | Nov 10 |
| Q4 2023 · Dec 31derived | $29.1M | — | — | −$18.7M | −$16.3M | — | -0.15 | −$33.2M | $356K | −$33.6M | Feb 26 |
| Q3 2023 · Sep 30 | $49.2M | — | — | $4.4M | $7.3M | — | 0.07 | −$34.5M | $198K | −$34.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $42.7M | — | −$215.4M | −$204.4M | -478.3% | -1.21 | −$187.5M | $718K | −$188.2M | — | — |
| FY2024 · to Dec 31 | $108.3M | — | −$110.4M | −$97M | -89.6% | -0.70 | −$151M | $938K | −$152M | — | — |
| FY2023 · to Dec 31 | $113.3M | — | −$68M | −$57.5M | -50.8% | -0.54 | −$19.4M | $1.1M | −$20.5M | — | — |
| FY2022 · to Dec 31 | $3.6M | — | −$162.7M | −$161.8M | -4434.7% | -2.05 | −$127.8M | $1.4M | −$129.1M | — | — |
| FY2021 · to Dec 31 | $41M | — | −$127M | −$122.2M | -298.4% | -2.36 | −$89M | $560K | −$89.6M | — | — |
| FY2020 · to Dec 31 | $20.1M | — | −$153.4M | −$149.9M | -746.7% | -3.82 | −$116M | $1.3M | −$117.3M | — | — |
Every number comes from Wave Life Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.